TAMPA, FLORIDA, UNITED STATES — February 17, 2026 TuHURA Biosciences has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for TBS-2025, a novel VISTA-inhibiting monoclonal antibody, to be studied in relapsed or refractory acute myeloid leukemia (AML). The investigational therapy will be evaluated in combination with a menin inhibitor in patients with mutNPM1 AML, a genetically defined high-risk leukemia subtype. Pending regulatory clearance, the company plans to initiate a Phase 2 clinical trial in early Q2 2026, marking a key transition from translational research to mid-stage clinical development.
Science Significance
TBS-2025 targets VISTA (V-domain Ig suppressor of T-cell activation), an emerging immune checkpoint highly expressed on myeloid cells and leukemic blasts. Scientific evidence indicates that leukemogenic mutations such as mutNPM1 and mutDNMT3A drive VISTA overexpression, enabling malignant cells to evade immune detection. By inhibiting this pathway, TBS-2025 is designed to restore immune surveillance and enhance anti-leukemic T-cell activity. Early clinical data from prior Phase 1 investigations demonstrated a favorable safety profile and pharmacologic activity, supporting further evaluation in hematologic malignancies. Combination with menin inhibitors — a newly approved therapeutic class — may provide synergistic immune activation and improved remission durability.
Regulatory Significance
The IND submission represents a foundational regulatory milestone enabling human clinical investigation in the United States. The application includes preclinical toxicology, pharmacokinetics, manufacturing quality data, and clinical study protocols required for FDA review. Approval of the IND would permit initiation of a Simon two-stage Phase 2 trial assessing safety and efficacy in menin inhibitor-naïve patients. Advancement into Phase 2 signals regulatory confidence in the therapy’s risk-benefit profile and development readiness, while also opening pathways toward potential accelerated approval if early efficacy benchmarks are met.
Business Significance
Advertisement
From a corporate strategy perspective, TBS-2025 strengthens TuHURA’s immuno-oncology pipeline focused on overcoming resistance to cancer immunotherapies. The asset was acquired through the company’s merger with Kineta Inc., expanding its monoclonal antibody portfolio. Successful clinical development could position TBS-2025 within a high-value hematologic oncology market, particularly as combination regimens gain prominence. Pipeline diversification through checkpoint modulation technologies enhances TuHURA’s long-term valuation and partnership potential within the rapidly evolving immunotherapy landscape.
Patients’ Significance
Relapsed or refractory AML remains one of the most difficult hematologic malignancies to treat, with poor survival outcomes and limited durable remission options. Although menin inhibitors have recently entered the therapeutic arsenal, response rates remain modest and often short-lived. By targeting immune evasion mechanisms, TBS-2025 may improve complete remission rates and extend treatment durability, offering new hope for patients with genetically defined, therapy-resistant disease. Combination immunotherapy approaches represent an important frontier in addressing relapse risk and improving long-term survival.
Policy Significance
Regulatory and public health agencies continue to prioritize innovation in hematologic oncology, particularly in genetically stratified cancers with high unmet need. IND activations for novel checkpoint inhibitors align with broader policy initiatives supporting accelerated oncology drug development, biomarker-driven trials, and combination therapy frameworks. Advancement of therapies targeting immune resistance pathways reflects global healthcare priorities to expand precision medicine and improve outcomes in aggressive blood cancers.
The IND filing for TBS-2025 marks a pivotal step in TuHURA Biosciences’ mission to overcome immunotherapy resistance in hematologic malignancies. By combining VISTA checkpoint inhibition with menin pathway targeting, the upcoming Phase 2 study aims to redefine treatment potential in relapsed AML. As regulatory review progresses and clinical data emerge, TBS-2025 could become a significant addition to next-generation immuno-oncology strategies designed to improve remission depth and patient survival.
Source: TuHURA Biosciences, Inc. press release
